Skip to content
Screener

Neurocrine Biosciences NBIX Q2 2026 earnings

Reported July 30, 2026 · After market close

Revenue$959.0MBeat by $67.8M
EPS$1.39Miss by $0.26
Revenue estimate$891.2M
EPS estimate$1.65
“As our commercial portfolio of first-in-class medicines continues to grow, so does our capacity to reinvest in innovation, advance a differentiated late-stage pipeline and pursue strategic opportunities that strengthen the company for the long term. With multiple important clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia, we are building an enduring company poised to deliver meaningful value for patients and shareholders for years to come.”
Kyle W. Gano

Next report

Nov 2, 2026 (Today)
Revenue estimate$1.0B
EPS estimate$1.91

Financials

Q2 2026

Income statement

See full
Revenue$959.0M+39.5%
Gross profit$935.8M+38.4%
Operating income$151.5M+4.1%
Net income$144.4M+34.3%
EPS (diluted)$1.39+31.1%

Balance sheet

See full
Cash & equivalents$332.4M+22.2%
Total debt$461.6M-5.8%
Total equity$3.7B+37.1%
Total assets$5.4B+37.8%

Cash flow

See full
Operating cash flow$136.4M+33.7%
CapEx$7.8M-37.6%
Free cash flow$128.6M+43.7%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$14.88B+8.1%
Enterprise value$15.01B+8.0%
P/E21.1×-11.1×
P/S4.4×-0.7×

Profitability

See full
Gross margin98%-0.5pp
Operating margin23.6%+3.8pp
Net margin20.9%+7.0pp
FCF margin25.8%+4.7pp

Returns & leverage

See full
Return on equity22.1%+8.7pp
Debt / equity0.1×-0.1×
Current ratio1.9×-1.3×

Segments

By segment

See full
Reportable Segment$959.0M+39.5%

By product

See full
Collaboration revenues$4.7M-14.5%

FAQ

When did Neurocrine Biosciences report Q2 2026 earnings?
Neurocrine Biosciences (NBIX) reported Q2 2026 earnings on July 30, 2026 after market close.
What were Neurocrine Biosciences's Q2 2026 revenue and EPS?
Neurocrine Biosciences reported revenue of $959.0M and eps of $1.39 for Q2 2026.
Did Neurocrine Biosciences beat estimates in Q2 2026?
Revenue beat the consensus estimate of $891.2M by $67.8M. EPS missed the consensus estimate of $1.65 by $0.26.
How did Neurocrine Biosciences's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 39.5% from $687.5M a year earlier and eps grew 31.1% from $1.06.
Where can I find Neurocrine Biosciences's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000914475-26-000035) and the 10-Q periodic report (0000914475-26-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.